Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis.

IF 2.8 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Diabetes & Vascular Disease Research Pub Date : 2022-09-01 DOI:10.1177/14791641221130043

Elisabeth B Stougaard, Peter L Kristensen, Urd Kielgast, Henrik U Andersen, Yasmin Hamid, Peter H Gæde, Esben Søndergaard, Gry H Dørflinger, Karen K Fjeldborg, Klavs W Hansen, Henrik H Thomsen, Thuraya M J Al-Imar, Michael Røder, Vikas S Sridhar, David Cherney, Peter Rossing, Frederik Persson

{"title":"Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis.","authors":"Elisabeth B Stougaard, Peter L Kristensen, Urd Kielgast, Henrik U Andersen, Yasmin Hamid, Peter H Gæde, Esben Søndergaard, Gry H Dørflinger, Karen K Fjeldborg, Klavs W Hansen, Henrik H Thomsen, Thuraya M J Al-Imar, Michael Røder, Vikas S Sridhar, David Cherney, Peter Rossing, Frederik Persson","doi":"10.1177/14791641221130043","DOIUrl":null,"url":null,"abstract":"Background: The indication for treatment of type 1 diabetes(T1D) with the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin has been withdrawn in Europe likely because of concern for diabetic ketoacidosis (DKA). We calculated the incidence of DKA in people with T1D treated with SGLT2i in Denmark.Methods: Clinical data from adults with T1D in Denmark were collected from nine outpatient clinics. Electronic health records made the search for DKA accurate.Results: From a population of 10.500 we observed 134 people treated with SGLT2i over a total period of 222 patient-years. Of those 72% were female, mean age (SD) was 51.4 (13.6) years and median duration of treatment (median, IQR) with an SGLT2i were 12.0 (6.0-29.0) months. The incidence of DKA was zero%.Conclusion: In 134 people with T1D treated with SGLT2i we found that none of the participants developed DKA during the treatment.","PeriodicalId":11092,"journal":{"name":"Diabetes & Vascular Disease Research","volume":" ","pages":"14791641221130043"},"PeriodicalIF":2.8000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e7/67/10.1177_14791641221130043.PMC9585567.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes & Vascular Disease Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/14791641221130043","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 2

Abstract

Background: The indication for treatment of type 1 diabetes(T1D) with the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin has been withdrawn in Europe likely because of concern for diabetic ketoacidosis (DKA). We calculated the incidence of DKA in people with T1D treated with SGLT2i in Denmark.

Methods: Clinical data from adults with T1D in Denmark were collected from nine outpatient clinics. Electronic health records made the search for DKA accurate.

Results: From a population of 10.500 we observed 134 people treated with SGLT2i over a total period of 222 patient-years. Of those 72% were female, mean age (SD) was 51.4 (13.6) years and median duration of treatment (median, IQR) with an SGLT2i were 12.0 (6.0-29.0) months. The incidence of DKA was zero%.

Conclusion: In 134 people with T1D treated with SGLT2i we found that none of the participants developed DKA during the treatment.

Abstract Image

查看原文本刊更多论文

1型糖尿病钠-葡萄糖共转运蛋白2抑制与糖尿病酮症酸中毒风险的现实生活评估

背景:钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)达格列净治疗1型糖尿病(T1D)的适应症在欧洲已经被撤销，可能是因为担心糖尿病酮症酸中毒(DKA)。我们计算了丹麦接受SGLT2i治疗的T1D患者中DKA的发生率。方法:收集丹麦9个门诊的成人T1D患者的临床资料。电子健康记录使得对DKA的搜索更加准确。结果:在10500个人群中，我们观察到134人在222患者年的总时间内接受了SGLT2i治疗。其中72%为女性，平均年龄(SD)为51.4(13.6)岁，SGLT2i的中位治疗时间(中位，IQR)为12.0(6.0-29.0)个月。DKA的发生率为0%。结论:在134例接受SGLT2i治疗的T1D患者中，我们发现没有参与者在治疗期间发生DKA。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes & Vascular Disease Research ENDOCRINOLOGY & METABOLISM-PERIPHERAL VASCULAR DISEASE

CiteScore

4.40

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Diabetes & Vascular Disease Research is the first international peer-reviewed journal to unite diabetes and vascular disease in a single title. The journal publishes original papers, research letters and reviews. This journal is a member of the Committee on Publication Ethics (COPE)